SCOUT-HCM data show LVOT gradient reductions persisted, patients switching from placebo responded similarly, and no patient had LVEF below 50%.
|Videos|November 5, 2021
Phosphate Binder Treatment Benefits Individuals With Advanced Stages of Chronic Kidney Disease
Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, discusses what the treatment options are to treat vascular calcification.
Advertisement
In a Pharmacy Times® interview, Paolo Raggi, MD, PhD, professor at the department of medicine in the division of cardiology at the University of Alberta, about his ASN 2021 Kidney Week presentation on the prevention of vascular calcification in chronic kidney disease.
He discussed what the treatment options are to treat vascular calcification.
Advertisement
Related to this article
A community oncology pharmacist explains how seeing patients across the course of their diagnosis builds trust and why accessibility remains the field’s biggest challenge despite advances in AI.
Christie Ballantyne, MD, explains how the CORALreef Extension study adds safety exposure and shows LDL-C lowering with oral enlicitide is sustained over time.
At SITC 2026, 10 of 15 patients with advanced melanoma responded to investigational amsokigene autoleucel at the recommended phase 2 dose, with 5 still in response 12 months after infusion.
The glucagon/GLP-1 dual agonist did not raise major adverse cardiovascular event risk in adults with obesity, but GI-related discontinuations were high.
Post hoc AHA 2026 data show the oral GLP-1 receptor agonist lowered systolic blood pressure across hypertension stages, partly beyond weight loss.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
Matthew Porteus, MD, PhD, highlighted preclinical advances in automated stem cell gene editing that could improve manufacturing scalability while supporting the development of next-generation genetic medicines.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Asundexian Receives FDA Approval, Becomes First FXIa Inhibitor for Secondary Stroke Risk Reduction
2
FDA Requires Class-Wide GLP-1 RA Labeling Changes for Potential NAION Risk
3
mRNA vs Protein-Based COVID-19 Vaccines: What Pharmacists Can Tell Patients
4
Oral PCSK9 Inhibitor Enlicitide Sustains LDL-C Reductions
5